|
|
|
de | fr | en Druckansicht
Projektverzeichnis
146-15 | Validation of a novel cell-based approach to study thyroidal physiology: Reduction and/or replacement of experiments with rodents Sykiotis, G., PhD, Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Lausanne, Switzerland | 145-15 | Combining computational modelling with in-vitro cellular responses in order to predict chemical impact on fish growth Schirmer, K., Prof. Dr., EAWAG, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, Switzerland | 144-15 | Development of in vitro three-dimensional multi-cellular culture models to study the role of heterotypic interactions during colorectal carcinomatous invasive process Rüegg, C., Prof. Dr., Department of OMI, University of Fribourg, Switzerland | 143-15 | An advanced in-vitro model of pulmonary inflammation based on a novel lung-on-chip technology Guenat, O., Prof. Dr., ARTORG Center, University of Bern & Pneumology and Thoracic Surgery Clinics, University Hospital of Bern, Switzerland | 142-14 | Validation of human stem-cell pluripotency using a bioreactor-based culturing system instead of a murine model to effect the development of embryoid bodies into teratomas De Geyter, C., Prof. Dr., Department of Biomedicine, Department of Biomedicine, University Hospital, University of Basel, Switzerland | 141-14 | In-vitro alternatives to in-vivo bioconcentration-testing in fish: restricted to rainbow trout or broadly applicable ? Segner, H., Prof., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Bern, Switzerland | 140-14 | Hydrocephalus simulator for testing of active ventriculoperitoneal shunts Schmid Daners, M., Dr., Institute for Dynamic Systems and Control, Department of Mechanical and Process Engineering, ETH Zurich, Switzerland | 139-14 | An in-vitro microvascular model of the endothelial barrier Herrmann, M., Dr., AO Research Institute Davos, Switzerland | 138-13 | Optimization of the nerve-cell-mimicking liposome assay as an in-vitro alternative for the detection of Clostridium-botulinum neurotoxins and for a validation of their presence in complex sample materials Avondet, M.-A., Toxinology Group, Spiez Laboratory, Switzerland | 137-13 | Validation of a new human in-vitro model of microglia Filgueira, L., Prof., Department of Medicine, University of Fribourg, Switzerland | 136-13 | Development of an in-vitro potency assay for the Clostridium chauvoei vaccines: Replacement of the guinea-pig-challenge potency test Frey, J., Prof., Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Switzerland | 135-13 | In-vitro engineering of a human cell-based threedimensional dynamic model of atherosclerosis Weber, B, Dr. Dr., Swiss Center for Regenerative Medicine, University Hospital Zurich, Switzerland | 134-12 | Cardiovascular simulator with autoregulation Vandenberghe S,, Prof., ARTORG Center for Biomedical Research, University of Bern, Switzerland | 133-12 | Development of an in vitro system to grow and investigate vascular endothelial cells under physiological flow conditions Rieben R., Prof., Department of Clinical Research, University of Bern, Switzerland | 132-12 | Identification of predictive in vitro markers of hematopoietic stem cell function Lutolf M. P., Prof., Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland | 131-12 | Antibody-phage-selection strategy for application in non-specialized laboratories Heinis Ch., Prof., Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland | 130-11 | Establishment of an in-vitro organ-slice defect model for meniscal repair in orthopaedic research Hunziker E., Prof., Center of Regenerative Medicine for Skeletal Tissues, University of Bern, Switzerland | 129-11 | The use of microfluidic chambers to study axonal transport in PTEN and SOCS3 dependent axonal regeneration He Zhigang, Prof., Children's Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115 | 128-11 | Genetic modification of the human airway epithelium – a paradigmatic system to study host responses to human respiratory viruses Thiel V., PD Dr., Institut für Immunbiologie, Kantonsspital St. Gallen, Switzerland | 127-11 | Establishing a novel system for quantitative production of murine basophils in vitro Kaufmann T., PD Dr., Institute of Pharmacology, University of Bern, Switzerland | 126-11 | Development and validation of a model to investigate myeloid-cell homeostasis Benarafa C., Dr., Theodor Kocher Institute, University of Bern, Switzerland | 125-11 | Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland; | 124-10 | Comparative in vitro and in vivo testing on biofilm formation on the surface of bone grafts Clauss M., Dr., Kantonsspital Liestal, Orthopädie, Liestal, Switzerland | 123-10 | Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values Rufli H., Dr., ecotoxsolution, Basel, Switzerland | 122-10 | Improved perioperative analgesia and reduced stress during recovery for the experimental animal: ultrasound-guided sciatic and femoral nerve block in sheep and quantitative assessment of block quality Rohrbach H., Dr, Institute for Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Switzerland | 121-10 | Organotypic spinal cord slices to study SCI and MS like lesions Chrast R., Prof. Dr., Department of Medical Genetics, University of Lausanne, Switzerland | 120-10 | Development of non-invasive strategies to study corticospinal neuron disease, injury and repair Jabaudon D., Prof. Dr., Dpt. of Basic Neurosciences, University of Geneva, Switzerland | 119-10 | Non invasive electrical monitoring of the population spiking activity in the central nervous system Gonzalez Andino S.L., Dr., University of Geneva and Geneva University Hospital, Switzerland | 118-10 | Engineering of an in vitro hepatocyte tissue system for malaria liver infection research Mancama D., Dr., Systems Biology, Biosciences Unit, CSIR, South Africa | 117-09 | Embryonic stem-cell-derived in-vitro model of tissue inflammation following confrontation with implant materials Wartenberg M., Prof. Dr., Friedrich Schiller University Jena and Justus Liebig University Giessen, Germany | 116-09 | Organotypic brain-slice cultures derived from regularly-slaughtered animals as an in-vitro alternative for the investigation of neuroinfectious diseases in ruminants Oevermann A., Dr., Vetsuisse Faculty, University of Berne, Switzerland | 115-09 | Engineering of a human brain tumour model to replace animal experimentation Preynat-Seauve O., Dr., University of Geneva, Switzerland | 114-08 | Reduction of the number of animals used in the Fish Acute Toxicity Test Rufli H., Dr., ecotoxsolution, Basel, Switzerland | 113-08 | Generic in-vitro evaluation assay for immunological correlates of protection to replace animal challenge infections Summerfield A., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland | 112-08 | A novel in-vitro model for the holistic assessment and optimisation of engineered tissue for functional cartilage repair Luo Z., Dr., Leeds Dental Institute, Leeds LS9 9LU, UK | 111-08 | Establishment of an organ ex-vivo tissue slice model for cardiovascular research in particular for therapeutic atherosclerosis targeting Hunziker P., PD Dr., Intensive Care Unit, University Hospital Basel, Switzerland | 110-08 | Development of an in-vitro assay for the screening of antischistosomal drugs Keiser J., Prof. Dr., Swiss Tropical Institute, University of Basel,Switzerland | 109-08 | Evaluation of lipid fractions for the substitution of serum in cell culture media Honegger P., Prof. Dr., Département de Physiologie, Université de Lausanne, Switzerland | 108-07 | Cultured piscine hepatocytes as an in-vitro source of metabolic clearance data that is currently gleaned by in-vivo bioaccumulation testing in fish Segner H., Prof. Dr., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Berne, Switzerland | 107-07 | Evaluation of an in vitro model to identify host parameters associated with virulence of Toxoplasma gondii strains D’Souza S., Dr., Pasteur Institute of Brussels-ISP,1180-Uccle, Belgium | 106-07 | Standardization and Pre-validation of MucilAir: A novel in vitro cell model of the human airway epithelium for testing acute and chronic effects of chemical compounds Huang S., Dr., Epithelix Sàrl, Plan-les-Ouates, Geneva, Switzerland | 105-06 | Establishment of an in vitro system for the prediction of the degree of virulence of classical swine fever virus isolates Ruggli N., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland | 104-06 | Development of in vitro strategies to propagate and characterize hemotrophic mycoplasmas Hofmann-Lehmann R., Prof. Dr., Clinical Laboratory, Vetsuisse-Faculty, University of Zurich, Switzerland | 103-06 | An in vitro Model of Central Nervous System Infection and Regeneration: Neuronal Stem Cells as Targets of Brain Damage & Regenerative Therapies in Bacterial Meningitis. Leib S.L., Prof. Dr., Institute of Infectious Diseases, University of Bern, Switzerland | 102-06 | Isolated, autologous blood-perfused heart: Replacement of heterotopic heart transplantation Bogdanova A, Dr., Institute of Veterinary Physiology, University of Zurich, Switzerland | 101-06 | Organotypic CNS slice cultures as an in-vitro model for immune mediated tissue damage and repair in multiple sclerosis Goebels N., Prof. Dr., Heinrich-Heine University Düsseldorf
Medical Faculty, Department of Neurology | 100-06 | Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland | 99-05 | The NEMO network
(Non-mammalian Experimental Models for the study of bacterial infections) Cosson P., Prof. Dr., Département de Physiologie Cellulaire et Métabolisme, Centre Medical Universitaire Genève, Geneva 4, Switzerland | 98-05 | Establishment of a murine syngeneic co-culture system of intestinal epithelial cells with intraepithelial T lymphocyte subsets. Mueller Ch., Prof. Dr., Institute of Pathology, University of Bern, Switzerland | 97-05 | Development of a three-dimensional enteric cell culture model for in vitro studies of the intestinal eukaryotic parasites Cryptosporidium spp. Mathis A., Prof. Dr., Institute of Parasitology, University of Zürich, Switzerland | 96-05 | Assessment of pain and stress in mice by monitoring gene expression changes Cinelli P., Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland | 95-05 | Development of QSAR-Models for Classification and Prediction of Baseline Toxicity and of Uncoupling of Energy Transduction Spycher S. + Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland | 94-04 | Tumor targeted reporter gene expression to improve and refine traditional models of Tumor growth and metastasis Vorburger S., Dr., Department of Clinical Research, Visceral and Transplantation Surgery,
University Hospital Bern, Switzerland | 93-04 | Development of a novel multicellular 3-dimensional blood brain barrier in vitro model Ogunshola O., Dr., Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zürich, Switzerland | 92-04 | Adjuvanticity of microbial-derived particles and synthetic analogs in vitro. Padovan E., Prof. Dr., Instituto Gulbenkian de Ciência, Oerias, Portugal | 91-04 | Establishment and validation of a Choroid Plexus Model to study drug transport Fricker G., Prof. Dr., Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls Universität Heidelberg, Germany | 90-03 | A non-mammalian system to study bacterial infections Cosson P., Prof. Dr., Centre Medical Universitaire, Dpt de Morphologie, Geneva 4, Switzerland | 89-03 | In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland | 88-03 | Assessing animal health and welfare and recognising pain and distress Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK | 87-03 | Information on serum free cell lines, an interactive database Strebel C., dipl. Ing. FH, CePower GmbH, Wädenswil, Switzerland | 86-03 | Bone Formation in a loading chamber for ex-vivo bone culture Richards R.G., Dr., AO Research Institute, Davos, Switzerland | 85-03 | Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland | 84-02 | Direct cloning of human antibodies from purified specific B-cells Wirthmueller U., Dr., Institute of Immunology, University Hospital Bern, Switzerland | 83-02 | The development of an in vitro intervertebral disc organ culture system Lee C., Dr., Biochemistry and Cell Biology Unit; AO Research Institute, Davos, Switzerland | 82-02 | Magnetic Resonance Imaging (MRI) for the non-invasive assessment of lung inflammation and pulmonary function in the rat Beckmann N., PD Dr., Novartis Pharma AG Basel
Novartis Institute of Biomedical Research (NIBR), Basel, Switzerland | 81-02 | In vitro model for the testing of endothelial cell activation and damage in whole blood Rieben R., Prof. Dr., Heart Transplantation Laboratory, Cardiology, University Hospital Bern, Switzerland | 80-01 | Induction of a primary T cell mediated immune response against drugs and drug metabolites in vitro Pichler, W.J., Prof. Dr., Division Allergology, University Hospital Bern, Switzerland | 79-01 | Screening methods for repellents and attachment deterrents for ticks in-vitro Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland | 78-01 | Validation of a combined perfusion/loading chamber for ex-vivo bone metabolic studies and bone-biomaterial interactions Richards R.G., Dr., AO Research Institute, Davos, Switzerland | 77-01 | Reproducibility and external validity of findings from animal experiments: influence of housing conditions Würbel H., Prof. Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland | 76-01 | Development of a model of heart angiogenesis in vitro Battegay E., Prof. Dr., Outpatient Department of Internal Medicine and Department of Research, University Hospital Basel, Switzerland | 75-00 | Internet laboratory for predicting harmful effects triggered by drugs and chemicals Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland
present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland | 74-00 | Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland | 73-00 | Generation and functional characterization of a clonal murine periportal Kupffer cell line from H-2Kb -tsA58 mice Landmann R., Prof. Dr., Division of Infectious Diseases, Department of Research, University Hospital Basel, Switzerland | 72-00 | Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland | 71-00 | Detection and characterisation of signs of pain in mice by the combined use of a telemetry model and behavioural observations Arras M., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland | 70-99 | Sensory irritant screening using a stable cell line expressing the vanilloid receptor Baumann T., Prof. Dr., Dept. of Neurological Suregry,Oregon Health and Sciences University, Portland, USA | 69-99 | A human neural cell line as in vitro model system for the excitotoxic cascade during stroke Bicker G., Prof. Dr., Abt. Zellbiologie, Physiologisches Institut, Stiftung Tierärztliche Hochschule Hannover, Germany | 68-99 | Genetic analysis of a 3D in vitro model of the rheumatic pannus tissue Illges H., PD Dr., Biotechnologie Institut Thurgau an der Universität Konstanz, Switzerland | 67-99 | Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland | 66-99 | The influence of enriched housing conditions on experimental results in laboratory mice Baumans V., Prof. Dr., Department of Laboratory Animal Science, University of Utrecht, Netherland | 65-98 | Reconstructed human epidermis as model for predicting irritancy Ponec M., Prof. Dr., Skin Research Laboratory, Department of Dermatology, Leiden University Medical Center, Netherland | 64-97 | Use of three-dimensional brain cell cultures as a model for ischemia-related research Honegger P., Prof. Dr., Institute of Physiology, Faculty of Medicine, University of Lausanne, Switzerland | 63-97 | In vitro study of pathogenesis of sepsis in a conditionally immortalized Kupffer cell line Landmann R., Prof. Dr., Division Infectious Deseases, Department Research, University Hospital Basel, Switzerland | 62-97 | Development of an in vitro model system for cartilage invasion by synovial fibroblasts Gay R. E., Prof. Dr., Department of Rheumatology, University Hospital Zürich, Switzerland | 61-97 | An in vitro model to study mechanical forces on human venous coronary bypass graft stenosis: Molecular targeting by pharmacological intervention Lüscher T. F., Prof. Dr., Cardiovascular Research, Institute of Physiology, University Zürich and Cardiology, University Hospital Zürich, Switzerland | 60-97 | Transgenic protozoa (Trypanosoma spp.) as an alternative to transgenic animals Roditi I., Prof. Dr., Institutes of General Microbiology and Parasitology, University of Bern, Switzerland | 59-97 | Phenotype characterisation and health monitoring of transgenic mice Mertens C., dipl. phil. nat., Zürcher Tierschutz (SPCA), Zürich, Switzerland | 58-97 | Development of laboratory housing conditions preventing stereotypic behaviour in Mongolian gerbils (Meriones unguiculatus) König B., Prof. Dr., Department of Animal Behaviour, Institute of Zoology, University of Zürich, Switzerland | 57-97 | Laboratory animal husbandry and welfare - Key strategic goals of future research Würbel H., Prof. Dr., Institute of Animal Sciences, Physiology and Animal Husbandry, Swiss Federal Institute of Technology (ETH), Switzerland | 56-96 | Development of a mimotope-based tetanus and diphtheria vaccine Stadler B. M., Prof. Dr., Institute of Immunology and Allergology, Inselspital, University of Berne, Switzerland | 55-96 | Computer-aided identification of ochratoxin antagonists Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland | 54-96 | Elaboration of an in vitro screening method for testing the effect of drugs and other compounds on the renal transport of uric acid Roch-Ramel F., Prof. Dr., Institute of Pharmacoly and Toxicology, University of Lausanne, Switzerland | 53-96 | Axenic cultivation of amastigote forms of Leishmania Grimm F., Dr. phil. nat., Institute of Parasitology, University of Zürich, Switzerland | 52-96 | Development of an interleukin-1 (IL-1) assay with rabbit blood as an alternative to the rabbit pyrogen test Hartung T., Prof.. Dr., Biochemical Pharmacology, University of Konstanz, Germany | 51-96 | Establishment of endotoxin limits in porcine vaccines: animal welfare aspects Cussler K., Dr., Paul Ehrlich Institut, Langen, Germany | 50-96 | Morphometric Analysis of human articular cartilage Hunziker E., Prof. Dr., M.E.Müller Institut für Biomechanik, University of Bern, Switzerland | 49-96 | Cours de formation continue universitaire intitulé “l’utilisation de l’animal en pharmaco/toxicologie et ses alternatives” Wagnières S., Dr. ès sciences, Service de formation continue, BEB, University of Lausanne, Switzerland | 48-96 | Utilization of a model of culture of human intestinal cell lines for the study of the pathogenicity of different strains of Clostridium difficile Kraehenbuhl J.-P., Prof. Dr., Institut Suisse de Recherches Expérimentales sur le Cancer (ISREC), Switzerland | 47-96 | Development of an in vitro system for the detection of estrogenic compounds (xenoestrogens) Fent K., PD Dr., Swiss Federal Institute for Environmental Science and Technology (EAWAG), Switzerland | 46-96 | Development and Validation of an In Vitro Model Simulating Mechanical Ventilation-Induced Inflammation Pugin J., Dr., Division des Soins Intensifs de Médecine, Hôpital Cantonal Universitaire, Genève, Suisse | 45-96 | Replacement of mouse and rat antibody production test by polymerase chain reaction assays Homberger F., Prof. Dr., Department of Microbiology and Immunology, Weill Medical College of Cornell University and the Memorial Sloaan-Kettering Center, USA | 44-95 | Establishment of a micro technique for corticosteroid receptor binding studies Hügin-Flores M., Dr., Psychopharmacology Unit, Department of Psychiatry, University Hospital, Geneva, Switzerland | 43-95 | Short term assay for liver cell activated neurotoxic drugs Maier P., Prof. Dr., Institute of Toxicology, Swiss Federal Institute of Technology (ETH) and University of Zürich, Switzerland | | 42-92 | Herstellung von Antikörpern: Einfluss der Adjuvantien auf die Immunantwort und die Belastung der Tiere Fischer R., Labor für Biochemie I
ETH Zürich, Zürich | 40-92 | Verwendung von Fischzellkulturen als Testsystem zur Reduktion und zum Ersatz von Tierversuchen in der Oekotoxikologie Fent K., PD Dr., EAWAG, Dübendorf | 39-92 | In vitro Isolation von pathogenen Trypanosomen aus Mensch, Haustier und Tsetsefliege Brun R.,
Kaminsky R., PD Dr.
PD Dr., Schweizerisches Tropeninstitut, Basel | 38-92 | CO2-Anästhesie beim Labortier Schatzmann U., Prof. Dr., Institut für Nutztiere und Pferde
Universität Bern, Bern | 37-92 | Nachweis von Clostridien-Toxinen ohne Tierversuch Nicolet J., Prof. Dr., Institut für Veterinärbakteriologie
Universität Bern, Bern | 36-92 | Ersatz tierischer Antikörper durch rekombinante antikörper-präsentierende Bakteriophagen Seebeck T., Prof. Dr., Institut für Allgemeine Mikrobiologie
Universität Bern, Bern | 35-92 | Nouvelle méthode de quantification de toxicité in vitro basée sur la modification de stress cellulaire Kolakofski D., Prof. PhD, Institut de Génétique et Microbiologie CMU
Centre Médical Universitaire, Genève | 34-92 | Validierungsstudie zur tierfreien in vitro Produktion von monoklonalen Antikörpern zusammen mit 31 Teilprojektteilnehmern Stiftung Forschung 3R, Stiftung Forschung 3R, Münsingen | 33-92 | Nachweis karzinogenese-relevanter Punktmutationen Lüthi J.,
Wegmüller B., PD Dr.
Dr., Institut für Biochemie
Universität Bern, Bern | 32-92 | A new model for in vitro corneal epithelial wound healing study Böhnke M., Prof. Dr., Universitäts Augenklinik
Inselspital, Bern | 30-92 | Toxikologische Untersuchung der Blutbildung in vitro Ryffel B., Dr., vormals Institut für Toxikologie
der ETH und Universität Zürich, Scherzenbach | 29-92 | Corticotrophin (ACTH) -Bestimmung in Arzneimitteln Weyers W., Fachapotheker, CONFARMA AG, Münchenstein, Schweiz | 28-92 | Analysis of the applicability of in vitro immunological methodologies to the study of foot-and-mouth disease vaccine efficacy McCullough K. Ch., Dr., Institut für Viruskrankheiten und Immunprophylaxe, IVI, Mittelhäusern | 27-92 | Entwicklung und Evaluation von Methoden zum Erfassen pyrogener Substanzen Jungi T. W., Prof. Dr., Institut für Veterinär-Virologie
Universität Bern, Bern | 26-92 | Produktion von monoklonalen Antikörpern mittels Repertoire Cloning Stadler B. M., Prof. Dr., Institut für Immunologie und Allergologie
Inselspital, Bern | 25-92 | Organotypic cultures: A model for pharmacological analysis in the central nervous system Muller D., Dr. med., Pharmacologie CMU
Centre Médical Universitaire, Genève | 24-91 | Nachweismethoden für enteropathogene E. coli (EPEC) beim Kalb Pospischil A., Prof. Dr., Institut für Veterinärpathologie
Universität Zürich, Zürich | 23-91 | Anästhesiemöglichkeiten bei der Ratte Becker M., PD Dr. med. vet., Kantonales Veterinäramt Basel Stadt
Abteilung Tierschutz, Basel | 22-91 | Screening Methode zur Abklärung des Abbaus von Cholesterin in vitro Niésor E., Dr., Symphar SA, Versoix | 21-91 | In vitro Herstellung von mAK mit Bioreaktoren II Fischer R., Labor für Biochemie I
ETH Zürich, Zürich | 20-90 | Verwendung eines menschlichen Darmzellkulturmodelles zur Reduktion und zum Ersatz von Tierversuchen auf dem Gebiet der Verdauungsphysiologie Hauri H. P., Prof. Dr., Abteilung Pharmakologie
Biozentrum Universität Basel, Basel | 19-90 | Remplacement des animaux dans les études sur Toxoplasma gondii II Pechère J. - C., Prof. Dr., Microbiologie CMU
Centre Médical Universitaire, Genève | 18-90 | In vitro Herstellung von mAK mit Bioreaktoren I Fischer R., Institut für Biochemie
ETH Zürich, Zürich | 17-90 | Einführung des Cell-Pharm für die mAK-Produktion Hübscher U., Prof. Dr., Institut für Pharmakologie und Biochemie
Universität Zürich, Zürich | 16-89 | Produktionseinheit zur Produktion von mAK Zinkernagel R., Prof. Dr., Institut für exp. Immunologie
Universitätsspital Zürich, Zürich | 15-88 | Validation of three in vitro toxicity / teratogenicity test systems using identical coded compounds (together with Swiss NSFP 17) Kucera P., Prof. Dr., Institut de Physiologie
Université de Lausanne, Lausanne | 13-88 | Endothelzellkulturen auf Cytodex-Microcarrier: Adhärenzmessung von neutrophilen Granulozyten in einem physiologischen System Zwahlen R., PD Dr. med. vet., Sektion Blutprodukte
Bundesamt für Gesundheitswesen, Bern | 12-88 | DNA-Replikationssystem zur tierfreien Wirkungs- und Toxizitäts-Testung Neftel K., Prof. Dr., Ziegler Spital, Bern | 11-88 | Tierschutzgerechte Euthanasie von Labortieren Schatzmann U., Prof. Dr., Institut für Nutztiere und Pferde
Universität Bern, Bern | 10-88 | Entwicklung eines künstlichen Fütterungssystems zur Zucht von Schildzecken Diehl P. A.,
Guerin P., Prof. Dr.
Dr., Institut de Zoologie
Université de Neuchâtel, Neuchâtel | 09-88 | In vitro Bestimmung schutzinduzierender Antigene in der Tollwutdiagnostik Bruckner L., Dr. med. vet., Institut für Viruskrankheiten und Immunprophylaxe, IVI, Mittelhäusern | 08-88 | Remplacement des animaux dans les études sur Toxoplasma gondii I Pechère J.- C., Prof. Dr., Microbiologie CMU
Centre Médical Universitaire, Genève | 07-88 | Erregungsleitung und Transporteigenschaften in Nerven und Epithelien Durand J., Prof. Dr., Institut de Physiologie
Université de Fribourg, Fribourg | 06-88 | Tierschonender Einsatz des Beagle Hundes in der Toxikologie Zbinden G., Prof. em. Dr. (verst.), Institut für Toxikologie
der ETH und Universität Zürich, Zürich | 05-87 | Kältekonservierung von Wurmparasiten Eckert J., Prof. em. Dr., Institut für Parasitologie
Universität Zürich, Zürich | 04-87 | Erkennung erbschädigender Substanzen an der Taufliege Drosophila Würgler F., Prof. em. Dr., Institut für Toxikologie
der ETH und Universität Zürich, Zürich | 03-87 | In vitro Test zum Nachweis des LCM-Virus Zinkernagel R., Prof. Dr., Institut für exp. Immunologie
Universitätsspital Zürich, Zürich | 02-87 | Menschliches Lebergewebe als Ersatz des Tierversuchs bei der Arzneimittelprüfung Meyer U. A., Prof. Dr., Biozentrum
Universität Basel, Basel | 01-87 | Verminderung von Tierversuchen in der Tollwut-Diagnostik durch Verbesserung der in vitro Diagnostik-Methoden Peterhans E., Prof. Dr., Institut für Veterinär-Virologie
Universität Bern, Bern |
|
|